Therapy and short-term prophylaxis of poxvirus infections: Historical background and perspectives

Antiviral Research

Volumn 57, Issue 1-2, 2003, Pages 25-33

  Neyts, Johan ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral; Cidofovir; Smallpox; Vaccinia

Indexed keywords

2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; 5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; ADENOSYLHOMOCYSTEINASE; CARBOXYLYASE; CIDOFOVIR; CYSTEINE DERIVATIVE; DNA POLYMERASE; ENZYME INHIBITOR; IDOXURIDINE; INOSINATE DEHYDROGENASE; INTERFERON; INTERFERON INDUCING AGENT; METISAZONE; NUCLEOSIDE DERIVATIVE; OROTODINE 5' MONOPHOSPHATE DECARBOXYLASE; RIBAVIRIN; RIFAMPICIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VIRUDOX;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; MOLLUSCUM CONTAGIOSUM; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SHORT COURSE THERAPY; VOMITING;

ANIMALIA; COWPOX VIRUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 0037282284     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00197-3     Document Type: Article

References (78)

1. Alford C.A. Jr., Whitley R.J. Treatment of infections due to herpesvirus in humans: a critical review of the state of the art. J. Infect. Dis. 133(Suppl.):1976;A101-A108.
2. Anonymous. From the Centers for Disease Control and Prevention, 1978. Human monkeypox - Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. JAMA 279, 189-190.
3. Bauer D.J. The antiviral and synergistic actions of isathin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br. J. Exp. Pathol. 36:1955;105-114.
4. Bauer D.J., St. Vincent L., Kempe C.H., Downie A.W. Prophylactic treatment of smallpox contacts with N-methylisatin β-thiosemicarbazone. Lancet. ii:1963;494-496.
5. Borchardt R.T. S-Adenosyl-L-methionine-dependent macromolecule methyltransferases: potential targets for the design of chemotherapeutic agents. J. Med. Chem. 23:1980;347-357.
6. Borchardt R.T., Keller B.T., Patel-Thombre U., Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccina virus multiplication in mouse L929 cells. J. Biol. Chem. 259:1984;4353-4358.
7. Bray M., Martinez M., Kefauver D., West M., Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 54:2002;129-142.
8. Bray M., Martinez M., Smee D.F., Kefauver D., Thompson E., Huggins J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:2000;10-19.
9. Cohen J., Marshall E. Vaccines for biodefense: a system in distress. Science. 294:2001;498-501.
10. Cools M., Balzarini J., De Clercq E. Mechanism of antiviral and cytotoxic action of (±)-6′β-fluoroaristeromycin, a potent inhibitor of S-adenosylhomocysteine hydrolase. Mol. Pharmacol. 39:1991;718-724.
11. Cundy K.C., Barditch-Crovo P., Petty B.G., Ruby A., Redpath M., Jaffe H.S., Lietman P.S. Clinical pharmacokinetics of 1-[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:1999;271-277.
12. Davies E.G.et al. Topical cidofovir for severe molluscum contagiosum. Lancet. 353:1999;2042.
13. De Clercq E. Antiviral and antitumor activities of 5-substituted 2′-deoxyuridines. Methods Find. Exp. Clin. Pharmacol. 2:1980;253-267.
14. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i.e., herpes-, papova-, pox- and adenovirus). Verh. K. Acad. Geneesk. Belg. 58:1996;19-49.
15. De Clercq, E., 1998. Antiviral agents that are active against CMV: potential of cidofovir for the treatment of CMV and other virus infections. In: Scholz, M., Rabenau, H.F., Doerr, H.W., Cinatl Jr., J. (Eds.), CMV-Related Immunopathology, Basel, Karger. Monogr. Virol. 21, 193-214.
16. De Clercq E. Vaccinia virus inhibitors as paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 14:2001;382-397.
17. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55:2002;1-13.
18. De Clercq E., Bergstrom D.E., Holý A., Montgomery J.A. Broad-spectrum antiviral activity of adenosine analogues. Antiviral Res. 4:1984;119-133.
19. De Clercq E., Bernaerts R., Shealy Y.F., Montgomery J.A. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem. Pharmacol. 39:1990;319-325.
20. De Clercq E., Cools M., Balzarini J., Marquez V.E., Borcherding D.R., Borchardt R.T., Drach J.C., Kitaoka S., Konno T. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives. Antimicrob. Agents Chemother. 33:1989;1291-1297.
21. De Clercq E., Cools M., Balzarini J., Snoeck R., Hosoya M., Shigeta S., Ueda T., Minakawa N., Matsuda A. Andrei, antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35:1991a;679-684.
22. De Clercq E., De Somer P. Effects of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions in mice infected with vaccinia virus. Appl. Microbiol. 16:1968;1314-1319.
23. De Clercq E., De Somer P. Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid. Science. 173:1971;260-262.
24. De Clercq E., De Somer P. Protection of rabbits against local vaccinia virus infection by Brucella abortus and polyacrylic acid in the absence of systemic interferon production. Infect. Immun. 8:1973;669-673.
25. De Clercq E., Luczak M., Shugar D., Torrence P.F., Waters J.A., Witkop B. Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc. Soc. Exp. Biol. Med. 151:1975;487-490.
26. De Clercq E., Montgomery J.A. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res. 3:1983;17-24.
27. De Clercq E., Murase J., Marquez V.E. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem. Pharmacol. 41:1991;1821-1829.
28. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:1987;261-272.
29. Descamps, J., De Clercq, E., 1978. Broad-spectrum antiviral activity of pyrazofurin (pyrazomycin). In: Siegenthaler, W., Lüthy, R. (Eds.), Current Chemotherapy. Proceedings of the 10th International Congress of Chemotherapy, Zürich, Switzerland, September 18-23, 1977. American Society for Microbiology, Washington, DC, 354 pp.
30. Domagk G., Behnisch R., Mietzch F., Schmidt H. Über eine neue, gegen Tuberkelbazillen in vitro wirksame Verbindungsklasse. Naturwissenschaften. 10:1946;315.
31. Enserink M. Smallpox vaccines. New cache eases shortage worries. Science. 296:2002;25-27.
32. Enserink M., Stone R. Public health. Dead virus walking. Science. 295:2001;2001-2005.
33. Fenner, F.J., White, D.O., 1970. Medical Virology (390 p.). Academic Press, New York, p. 190.
34. Geerinck K. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:2001;543-549.
35. Hasobe M., McKee J.G., Borcherding D.R., Borchardt R.T. 9-(Trans-2′, trans-3′-dihydroxycyclopent-4′-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob. Agents Chemother. 31:1987;1849-1851.
36. Heiner G.G., Fatima N., Russell P.K., Haase A.T., Ahmad N., Mohammed N., Thomas D.B., Mack T.M., Khan M.M., Knatterud G.L., Anthony R.L., McCrumb F.R. Jr. Field trials of methisazone as a prophylactic agent against smallpox. Am. J. Epidemiol. 94:1971;435-449.
37. Heymann D.L., Szczeniowski M., Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br. Med. Bull. 54:1998;693-702.
38. Huggins, J.W., Baker, R.O., Beadle, J.R., Hostetler, K.Y., 2002. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Abstracts of the 15th International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002. Antiviral Res. 53 (104), A66.
39. Hutin Y.J., Williams R.J., Malfait P., Pebody R., Loparev V.N., Ropp S.L., Rodriguez M., Knight J.C., Tshioko F.K., Khan A.S., Szczeniowski M.V., Esposito J.J. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. Emerg. Infect. Dis. 7:2001;434-438.
40. Ibarra V.et al. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm. Venereol. 80:2000;315-316.
41. Kaplan E.H., Craft D.L., Wein L.M. Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10935-10940.
42. Kern E.R., Hartline C., Harden E., Keith K., Rodriguez N., Beadle J.R., Hostetler K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:2002;991-995.
43. Kesson A.M., Ferguson J.K., Rawlinson W.D., Cunningham A.L. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin. Infect. Dis. 25:1997;911-914.
44. Korngold R., Doherty P.C. Treatment of mice with polyinosinic-polycytidilic polyribonucleotide reduces T-cell involvement in a localized inflammatory response to vaccinia virus challenge. J. Virol. 53:1985;489-494.
45. Levy H.B., Lvovsky E. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits. J. Infect. Dis. 137:1978;78-81.
46. Meadows K.P. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch. Dermatol. 133:1997;987-990.
47. Moss, B., 2001. Poxviridae: the viruses and their replication. In: Knipe, D.M., Howley, P.P. (Eds.), Fields Virology, 4th ed. Lipincott Williams & Wilkins, pp. 2849-2883.
48. Mukinda V.B., Mwema G., Kilundu M., Heymann D.L., Khan A.S., Esposito J.J. Re-emergence of human monkeypox in Zaire in 1996. Monkeypox Epidemiologic Working Group. Lancet. 349:1997;1449-1450.
49. Müller, W.E.G., 1979. Mechanism of action and pharmacology: chemical agents. In: Galasso, G.J., Merigan, T.C., Buchanan, R.A. (Eds.), Antiviral Agents and Viral Diseases of Man. Raven Press, New York, pp. 77-149.
50. Naesens L., Snoeck R., Andrei G., Balzarini J., Neyts J., De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. 8:1997;1-23.
51. Neyts J., Balzarini J., Andrei G., Chaoyong Z., Snoeck R., Zimmerman A., Mertens T., Karlsson A., De Clercq E. Intracellular metabolism of the N7-substituted acyclic nucleoside analog 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a potent inhibitor of herpesvirus replication. Mol. Pharmacol. 53:1998;157-165.
52. Neyts J., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:1993;242-246.
53. Neyts J., De Clercq E. Efficacy of 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine for the treatment of vaccinia (orthopox-) virus infections in mice. Antimicrob. Agents Chemother. 45:2001;84-87.
54. Neyts J., De Clercq E. Effect of 5-iodo-2′-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 46:2002;2842-2847.
55. Nutt R.F., Dickinson M.J., Holly F.W., Walton E. Branched-chain sugar nucleosides. III. 3′-C-methyladenosine. J. Org. Chem. 33:1968;1789-1795.
56. Obara T., Shuto S., Saito Y., Snoeck R., Andrei G., Balzarini J., De Clercq E., Matsuda A. New neplanocin analogues. 7. Synthesis and antiviral activity of 2-halo derivatives of neplanocin A. J. Med. Chem. 39:1996;3847-3852.
57. Patil S.D., Schneller S.W., Hosoya M., Snoeck R., Andrei G., Balzarini J., De Clercq E. Synthesis and antiviral properties of (±)-5′-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. J. Med. Chem. 35:1992;3372-3377.
58. Redfield R.R., Wright D.C., James W.D., Jones T.S., Brown C., Burke D.S. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:1987;673-676.
59. Robins M.J., Wnuk S.F., Yang X., Yuan C.-S., Borchardt R.T., Balzarini J., De Clercq E. Inactivation of S-adenoysl-L-homocysteine hydrolase and antiviral activity with 5′,5′,6′,6′-tetradehydro-6′-deoxy-6′- halohomoadenosine analogues (4′-haloacetylene analogues derived from adenosine). J. Med. Chem. 41:1998;3857-3864.
60. Shuto S., Obara T., Saito Y., Andrei G., Snoeck R., De Clercq E., Matsuda A. New neplanocin analogues. 6. Synthesis and potent antiviral activity of 6′-homoneplanocin A. J. Med. Chem. 39:1996;2392-2399.
61. Shuto S., Obara T., Toriya M., Hosoya M., Snoeck R., Andrei G., Balzarini J., De Clercq E. New neplanocin analogues. 1. Synthesis of 6′-modified neplanocin A derivatives as broad-spectrum antiviral agents. J. Med. Chem. 35:1992;324-331.
62. Siddiqi S.M., Chen X., Schneller S.W., Ikeda S., Snoeck R., Andrei G., Balzarini J., De Clercq E. Antiviral enantiomeric preference for 5′-noraristeromycin. J. Med. Chem. 37:1994a;551-554.
63. Siddiqi S.M., Chen X., Schneller S.W., Ikeda S., Snoeck R., Andrei G., Balzarini J., De Clercq E. An epimer of 5′-noraristeromycin and its antiviral properties. J. Med. Chem. 37:1994b;1382-1384.
64. Siddiqi S.M., Chen X., Rao J., Schneller S.W., Ikeda S., Snoeck R., Andrei G., Balzarini J., De Clercq E. 3-Deaza- and 7-deaza-5′-noraristeromycin and their antiviral properties. J. Med. Chem. 38:1995;1035-1038.
65. Sidwell R.W., Allen L.B., Khare G.P., Huffman J.H., Witkowski J.T., Simon L.N., Robins R.K. Effect of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob. Agents Chemother. 3:1973;242-246.
66. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., Robins R.K. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 177:1972;705-706.
67. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antiviral Chem. Chemother. 12:2001;71-76.
68. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res. 54:2002a;113-120.
69. Smee D.F., Sidwell R.W., Kefauver D., Bray M., Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox. Antimicrob. Agents Chemother. 46:2002b;1329-1335.
70. Smee D.F., Bailey K.W., Wong M., Sidwell R.W. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 47:2000;171-177.
71. Smee D.F., Bailey K.W., Wong M.H., Sidwell R.W. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52:2001a;55-62.
72. Subak-Sharpe J.H., Timbury M.C., Williams J.F. Rifampicin inhibits the growth of some mammalian viruses. Nature. 222:1969;341-345.
73. Toro J.R., Wood L.V., Patel N.K., Turner M.L. Topical cidofovir. A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch. Dermatol. 136:2000;983-985.
74. Tseng C.K.H., Marquez V.E., Fuller R.W., Goldstein B.M., Haines D.R., McPherson H., Parsons J.L., Shannon W.M., Arnett G., Hollingshead M., Driscoll J.S. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem. 32:1989;1442-1446.
75. Van Aerschot A., Mamos P., Weyns N.J., Ikeda S., De Clercq E., Herdewijn P. Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents. J. Med. Chem. 36:1993;2938-2942.
76. Walton E., Jenkins S.R., Nutt R.F., Holly F.W., Nemes M. Branched-chain sugar nucleosides. V. Synthesis and antiviral properties of several branched-chain sugar nucleosides. J. Med. Chem. 12:1969;306-309.
77. Winegarden, K.L., Ciesla, S.L., Aldern, K.A., Beadle, J.R., Hostetler, K.Y., 2002. Oral pharmacokinetics and preliminary toxicology of 1-O-hexadecyloxypropyl-cidofovir in mice. Abstracts of the 15th International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002. Antiviral Res. 53 (105), A67.
78. Zabawski E.J., Cockerell C.J. Topical cidofovir for molluscum contagiosum in children. Pediatr. Dermatol. 16:1999;414-415.